1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Biochemical and Behavioral Characterization of Novel Methylphenidate Analogs

Biochemical and Behavioral Characterization of Novel Methylphenidate Analogs

  1. davestate
    As part of a project to develop treatment agents for cocaine abuse, ()-threo-methylphenidate (TMP) and 11 analogs were characterized biochemically and behaviorally to assess their
    potential as anti-cocaine medications. The compounds contained aryl and/or nitrogen substitutions, and/or replacement of the ester function by an alcohol or ether. All of the analogs, except for the N-methyl-substituted compounds, showed increased inhibitory potency against 3H-()-2--carbomethoxy-
    3--(4-fluorophenyl)tropane 1,5-naphthalenedisulfonate ([3H]WIN 35,428) ([3H]WIN) binding to the dopamine transporter, compared with TMP.
    In general, parallel results were obtained for inhibition of [3H]dopamine ([3H]DA) uptake. Although
    compounds with N-substitutions were proportionally less potent at blocking DA uptake than WIN binding (compared with the unsubstituted compounds), one such compound that was 6-fold more potent against [3H]WIN binding than [3H]DA uptake did not attenuate inhibition by cocaine of synaptosomal
    [3H]DA transport. The compounds were significantly less potent in displacing [3H]citalopram binding from the serotonin transporter.

    American Society for Pharmacology and Experimental Therapeutics 4691/977159
    JPET 301:527–535, 2002
    M. M. SCHWERI, H. M. DEUTSCH, A.T. MASSEY,1 AND S. G. HOLTZMAN

    In cocaine discrimination studies in rats, all but two of the analogs (both N-substituted) completely generalized with the cocaine stimulus. Robust positive correlations were observed
    between potency in the drug discrimination assay and activity at the dopamine transporter, but not the serotonin transporter. When tested for their ability to alter cocaine discrimination,
    four of the analogs (three of which had N substitutions and shallow dose-response curves as cocaine
    substitutes) actually enhanced cocaine discrimination, often at combined doses of cocaine and test compound that were inactive when given separately. Taken together, the results suggest that TMP analogs may have potential as substitution therapies for the treatment of cocaine abuse